Edition:
India

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.07USD
18 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.07
Open
$2.07
Day's High
$2.10
Day's Low
$2.01
Volume
17,193
Avg. Vol
42,361
52-wk High
$2.71
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Bellerophon Q4 Loss Per Share $0.44
Friday, 16 Mar 2018 

March 15 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.44.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon qtrly loss per share $0.39
Tuesday, 9 Aug 2016 

Bellerophon Therapeutics Inc : Bellerophon reports second quarter 2016 financial results and provides business update . Qtrly loss per share $0.39 . Company believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months . Believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months .Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Bellerophon enrolls first patient in phase 3 trial for pulmonary arterial hypertension
Thursday, 16 Jun 2016 

Bellerophon Therapeutics Inc :1 phase 3 clinical trial for pulmonary arterial hypertension (pah).  Full Article

Bellerophon reports Q1 loss per share $0.54
Tuesday, 10 May 2016 

Bellerophon Therapeutics Inc : Bellerophon reports first quarter 2016 financial results and provides business update . Qtrly loss per share $0.54 .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS